ClinicalTrials.gg
TerminatedNCT03334812ACIUpdated Oct 7, 2021Results posted

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

A Phase 2 interventional study of LNA043 and placebo to LNA043 in Knee Cartilage Lesion, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in Austria. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-10-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was terminated early based on an interim analysis of 14 subjects, which demonstrated a favorable safety and tolerability profile.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study was to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a single intra-articular (i.a.) administration of LNA043 in regenerating the articular cartilage of the knee, in a standardized clinical scenario of acute cartilage defect. The study aimed at characterizing the mechanism of action of LNA043

Read the detailed description

This was a non-confirmatory, patient and investigator blinded, randomized, placebo-controlled, parallel group, single dose study in patients with cartilage lesions undergoing autologous cartilage implantation (ACI). Participants were treated only on one occasion (Day 1) with a single i.a. injection that was performed under arthroscopic visualization and followed up for 28 weeks.

Originally approximately 22 patients were planned to be enrolled in two cohorts (LNA043 20 mg and LNA043 40 mg). The study was terminated before any patient was randomized into the LNA043 40 mg cohort

02

Conditions studied

  • Knee Cartilage Lesion

Keywords

  • cartilage lesion, ACI
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed
  • Patient is ≥18 and≤ 50 years old at time of screening
  • Patient has a (BMI) \<30 kg/m2 at screening
  • Patient has a localized articular cartilage defect of the knee and is scheduled for an ACI procedure
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Patient has radiologically apparent degenerative joint disease in the target knee as determined by Kellgren and Lawrence grade ≥2 based on X-ray evaluation performed within 6 months from screening
  • Patient has unstable knee joint or insufficiently reconstructed ligaments, based on medical history and physical examination by the investigator.
  • Patient scheduled for a concomitant articular surgical procedure (e.g., anterior cruciate ligament reconstruction) other than debridement or partial meniscectomy
  • Patient has malalignment (valgus- or varus-deformity) in the target knee ≥ 5° based on based on X-ray evaluation performed within 6 months from screening.at screeningmedical history. In suspected cases, the mechanical axis must be established radiographically through complete leg imaging during standing and in postero-anterior projection.
  • Patient has a known disease, inflammatory arthropathy (including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, CPPD, gout), active acute or chronic infection of the joint, recent Lyme disease to the knee, systemic cartilage disorder, or a known systemic connective tissue disease.
  • Patient has had surgical treatment of the target knee using autologous osteochondral transplantation/mosaicplasty within 12 months prior to screening (Note: prior diagnostic arthroscopy with debridement and lavage, meniscal surgery, microfracture, anterior cruciate ligament reconstruction, and extra-articular surgery e.g., high-tibial osteotomy are acceptable).
  • Patient is unable to undergo magnetic resonance imaging (MRI) or presents absolute to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator).
  • Patient taking medications prohibited by the protocol: by any route (except topical) from 4 weeks prior to screening; nonsteroidal anti-inflammatories or aspirin (greater than 100 mg per day) within 2 weeks prior to screening; paracetamol greater than 3000 mg per day within 2 weeks prior to screening; glucosamine or chondroitin sulfate within 2 weeks prior to screening; any local treatment i.a. into the knee within 3 months from screening.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 15 days after stopping of drug.
  • Regular smokers (use of tobacco/nicotine products in the previous 3 months > 5 cigarettes/day). Urine cotinine levels will be measured during screening for all subjects. Regular smokers will be defined as any subject who reports tobacco use of > 5 cigarettes/day and/or who has a urine cotinine ≥ 500 ng/mL.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    LNA043 20mg/ml

    LNA043 20mg/ml single dose

    Biological: LNA043

  • Placebo comparator
    Matching placebo to 20mg

    Matching placebo to 20mg/3ml, single dose

    Biological: placebo to LNA043

  • Experimental
    LNA043 40mg/ml

    LNA043 40mg/ml single dose

    Biological: LNA043

  • Placebo comparator
    Matching placebo to 40mg

    Matching placebo to 40mg/4ml, single dose

    Biological: placebo to LNA043

Interventions

  • BiologicalLNA043

    LNA043 Single dose

  • Biologicalplacebo to LNA043

    placebo to LNA043 single dose

06

What researchers measure

Primary outcomes

  1. Change From Baseline in GAG Content

    Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content were assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB and the defect to be treated (DTBT or main lesion) to healthy weight bearing region (HWB), i.e. DTBT/HWB was of major interest

    Time frame: Baseline, Week 4

  2. Bi-layer Collagen Organization Based on MRI Measurements

    MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the surgically created defect (SCD) and defect to be treated (DTBT) cartilage regions.

    Time frame: Week 4

Secondary outcomes

  1. Change From Baseline in International Cartilage Repair Society (ICRS) Scoring

    Extent of the repair tissue at the donor site before surgery. Each criterion was evaluated based on the visual analog scale and graded from 0 (best) to 100 (worst).

    Time frame: Week 4

  2. Percentage of Donor Site Refilling Based on MRI Measurements.

    Extent of filling of the donor site over a longer term. Percentage change from baseline in refilling of cartilage defect based on 7T MRI for donor Region.

    Time frame: Baseline, Week 4, Week 12 and Week 28

  3. Change From Baseline in GAG Content

    Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content was assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB was of major interest

    Time frame: Baseline, Week 12 and Week 28

  4. Bi-layer Collagen Organization Based on MRI Measurements

    MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the SCD cartilage region.

    Time frame: Week 12 and Week 28

  5. PK Profile of LNA043 and of AngPTL3 in Serum Cmax

    Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration

    Time frame: 4 weeks

  6. PK Profile of LNA043 and of AngPTL3 in Serum AUC

    Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration

    Time frame: 4 weeks

  7. Number of Participants With Anti-LNA043 Antibodies in Serum

    Potential immunogenicity of LNA043

    Time frame: Baseline, Week 1, Week 4, Week 12 and Week 28

07

Results

Posted Apr 17, 2020

Participant flow

All patients were recruited from 3 clinical sites in Austria.

Participant flow — Overall Study
MilestoneLNA043 20mgMatching Placebo to 20mgLNA043 40mgMatching Placebo to 40mg
Started9500
Completed9500
Not completed0000

Outcome measures

PrimaryChange From Baseline in GAG Content

Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content were assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB and the defect to be treated (DTBT or main lesion) to healthy weight bearing region (HWB), i.e. DTBT/HWB was of major interest

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Ratio
Change From Baseline in GAG Content
RatioLNA043 20mgMatching Placebo to 20mg
SCD/HNWB0.24 ± 0.060.06 ± 0.12
DTBT/HWB0.08 ± 0.040.09 ± 0.09
Statistical analysis
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.1219 · Mean difference (net): 0.18 · 95% CI -0.15 to 0.51
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.5438 · Mean difference (net): -0.01 · 95% CI -0.28 to 0.25
PrimaryBi-layer Collagen Organization Based on MRI Measurements

MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the surgically created defect (SCD) and defect to be treated (DTBT) cartilage regions.

Time frame:
Week 4
Reported as:
Mean · Ratio
Bi-layer Collagen Organization Based on MRI Measurements
RatioLNA043 20mgMatching Placebo to 20mg
Bi-layer Collagen Organization Based on MRI Measurements1.01 ± 0.070.95 ± 0.09
Statistical analysis
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.3067 · Mean difference (final values): 0.06 · 95% CI -0.19 to 0.31
SecondaryChange From Baseline in International Cartilage Repair Society (ICRS) Scoring

Extent of the repair tissue at the donor site before surgery. Each criterion was evaluated based on the visual analog scale and graded from 0 (best) to 100 (worst).

Time frame:
Week 4
Reported as:
Mean · Unit on a scale
Change From Baseline in International Cartilage Repair Society (ICRS) Scoring
Unit on a scaleLNA043 20mgMatching Placebo to 20mg
Abnormal Calcification/Ossification98.75 ± 1.05100.00 ± 1.48
Cell Morphology61.43 ± 14.1456.67 ± 21.60
Chondrocyte clustering85.71 ± 8.3785.00 ± 12.78
Inflammation92.50 ± 2.1598.75 ± 3.04
Matrix Staining57.14 ± 12.1725.00 ± 18.59
Overall assessment49.29 ± 12.2355.00 ± 18.68
Tissue Morphology71.43 ± 7.7865.00 ± 11.88
Vascularisation in repaired tissue66.25 ± 12.8877.50 ± 18.21
Basal Integration82.86 ± 10.6490.00 ± 16.26
Formation of a Tidemark65.71 ± 18.1563.33 ± 27.72
Mid/Deep zone assessment50.00 ± 14.5656.67 ± 22.24
Subcondral bone abnormalities/marrow fibrosis73.75 ± 13.4577.50 ± 19.01
Surface Architecture57.86 ± 11.3380.00 ± 17.31
Surface/Superficial assessment56.43 ± 11.4283.33 ± 17.44
SecondaryPercentage of Donor Site Refilling Based on MRI Measurements.

Extent of filling of the donor site over a longer term. Percentage change from baseline in refilling of cartilage defect based on 7T MRI for donor Region.

Time frame:
Baseline, Week 4, Week 12 and Week 28
Reported as:
Least squares mean · Percent
Percentage of Donor Site Refilling Based on MRI Measurements.
PercentLNA043 20mgMatching Placebo to 20mg
Week 464.38 ± 7.8038.15 ± 11.03
Week 1260.25 ± 14.5532.44 ± 19.09
Week 28 (EOS)86.53 ± 11.0962.73 ± 14.52
Statistical analysis
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.0404 · Mean difference (net): 26.23 · 95% CI -3.86 to 56.32
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.1381 · Mean difference (net): 27.82 · 95% CI -26.5 to 82.10
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Models Analysis · p = 0.1168 · Mean difference (net): 23.80 · 96% CI -19.3 to 66.89
SecondaryChange From Baseline in GAG Content

Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content was assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB was of major interest

Time frame:
Baseline, Week 12 and Week 28
Reported as:
Least squares mean · Ratio
Change From Baseline in GAG Content
RatioLNA043 20mgMatching Placebo to 20mg
SCD/HNWB - Week 120.14 ± 0.070.15 ± 0.09
SCD/HNWB - Week 280.33 ± 0.100.14 ± 0.14
Statistical analysis
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.5175 · Mean difference (net): -0.01 · 95% CI -0.26 to 0.25
  • LNA043 20mg vs Matching Placebo to 20mg · Mixed Effect Model Repeat Measurement · p = 0.1476 · Mean difference (net): 0.19 · 95% CI -0.22 to 0.60
SecondaryBi-layer Collagen Organization Based on MRI Measurements

MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the SCD cartilage region.

Time frame:
Week 12 and Week 28
Reported as:
Mean · Ratio
Bi-layer Collagen Organization Based on MRI Measurements
RatioLNA043 20mgMatching Placebo to 20mg
Week 121.44 ± 0.151.57 ± 0.18
Week 281.33 ± 0.111.45 ± 0.14
SecondaryPK Profile of LNA043 and of AngPTL3 in Serum Cmax

Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration

Time frame:
4 weeks
Reported as:
Mean · ng/mL
PK Profile of LNA043 and of AngPTL3 in Serum Cmax
ng/mLLNA043 20mgMatching Placebo to 20mg
LNA04357.4 ± 22.1—
AngPTL322.9 ± 9.0326.6 ± 7.62
SecondaryPK Profile of LNA043 and of AngPTL3 in Serum AUC

Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration

Time frame:
4 weeks
Reported as:
Mean · hr*ng/mL
PK Profile of LNA043 and of AngPTL3 in Serum AUC
hr*ng/mLLNA043 20mgMatching Placebo to 20mg
LNA043821 ± 349—
AngPTL33130 ± 14403030 ± 1060
SecondaryNumber of Participants With Anti-LNA043 Antibodies in Serum

Potential immunogenicity of LNA043

Time frame:
Baseline, Week 1, Week 4, Week 12 and Week 28
Reported as:
Count of participants · Participants
Number of Participants With Anti-LNA043 Antibodies in Serum
ParticipantsLNA043 20mgMatching Placebo to 20mg
Day 1: anti-LNA043 antibodies present — YES00
Day 1: anti-LNA043 antibodies present — NO95
Day 8: anti-LNA043 antibodies present — YES00
Day 8: anti-LNA043 antibodies present — NO95
Day 29: anti-LNA043 antibodies present — YES00
Day 29: anti-LNA043 antibodies present — NO95
Day 85: anti-LNA043 antibodies present — YES00
Day 85: anti-LNA043 antibodies present — NO95
Day 197: anti-LNA043 antibodies present — YES00
Day 197: anti-LNA043 antibodies present — NO95

Adverse events

Collected over Adverse events were collected from the dose of study treatment until up to 28 weeks post treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LNA043 20mg0/9 (0%)0/9 (0%)4/9 (44.4%)
Placebo0/5 (0%)0/5 (0%)4/5 (80%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventLNA043 20mgPlacebo
NauseaGastrointestinal disorders0/92/5
HeadacheNervous system disorders2/90/5
Thyroid massEndocrine disorders0/91/5
NasopharyngitisInfections and infestations0/91/5
Urinary tract infectionInfections and infestations0/91/5
Joint range of motion decreasedMusculoskeletal and connective tissue disorders0/91/5
VertigoEar and labyrinth disorders1/90/5
Influenza like illnessGeneral disorders1/90/5
ContusionInjury, poisoning and procedural complications1/90/5
FallInjury, poisoning and procedural complications1/90/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)LNA043 20mgMatching Placebo to 20mgTotal
Mean31.0 ± 6.1639.4 ± 7.4034.0 ± 7.60
Sex: Female, Male
Sex: Female, Male(Participants)LNA043 20mgMatching Placebo to 20mgTotal
Female358
Male606
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LNA043 20mgMatching Placebo to 20mgTotal
White9514
08

Study locations

2 sites
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Wien, 1180, Austria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Apr 2019, 17 months.

Results were first posted in Apr 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2017
First posted
Nov 7, 2017
StartActual
Oct 18, 2017
Primary completionActual
Apr 5, 2019
CompletionActual
Apr 5, 2019
Results first posted
Apr 17, 2020
Last update
Oct 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03334812
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Oct 18, 2017
Primary completion
Apr 5, 2019
Completion
Apr 5, 2019
Results posted
Apr 17, 2020
Last update
Oct 7, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LNA043

Start the discussion